Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Quick Primer On Roche's Immuno-Oncology Assets

Executive Summary

Roche's broad cancer immunotherapy pipeline features a dozen novel agents, including the first candidates from new therapeutic platforms for bispecific antibodies and personalized cancer vaccines.


Related Content

The IO Switch: Making Tumor-Associated Macrophages Work In Our Favor
BioNTech, Neon Take A Step Forward In Personalized Cancer Vaccines
NewLink Absorbs Big Blow As Roche Exits IDO Inhibitor Partnership
Keytruda Approval Opens New Routes For Immuno-Oncology
Scrip's Rough Guide To IDO
Avastin Redux? Genentech’s Tecentriq Trial Failure Puts Bladder Cancer Claim At Risk
Genentech, BioNTech Pact Aims To Make Targeted Cancer Vaccines
Roche Sees Biomarker-Guided Discovery As Key To Unlocking Tumor Microenvironment


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts